Trials / Unknown
UnknownNCT03601975
Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 336 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase III randomized controlled multi-center trial comparing anlotinib plus Gemcitabine/Cisplatin with placebo plus Gemcitabine/Cisplatin in previous untreated patients with recurrent/metastatic Nasopharyngeal Carcinoma, in order to verify the efficacy and security of anlotinib in mNPC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine/Cisplatin | gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle |
Timeline
- Start date
- 2018-08-27
- Primary completion
- 2020-07-30
- Completion
- 2021-07-30
- First posted
- 2018-07-26
- Last updated
- 2019-02-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03601975. Inclusion in this directory is not an endorsement.